Product logins

Find logins to all Clarivate products below.


Hypertension | Current Treatment: Physician Insights | US | 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different classes. Nevertheless, despite the numerous treatment options, significant unmet need remains in the treatment of resistant hypertension, which is defined as inadequately controlled BP despite the concurrent use of three or more antihypertensive agents. This report provides cardiologist insight into prescribing patterns for hypertension and especially resistant hypertension.

Questions Answered:

  • What patient shares do angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) garner in the U.S. hypertension market? What are the trends in prescribing for resistant hypertension?
  • How do physicians diagnose resistant hypertension, and how does this diagnosis influence their treatment approach?
  • What factors constrain and what factors drive choice of hypertension treatment?
  • What percentage of hypertensive patients receive monotherapy versus combination therapy?

Product Description:

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

GEOGRAPHY: United States

PRIMARY RESEARCH: Survey of 100 U.S. cardiologists

KEY DRUGS COVERED: ACE inhibitors, ARBs, diuretics, calcium channel blockers, beta blockers, aldosterone antagonists, mineralocorticoid receptor antagonists (MRAs), diuretics, direct renin inhibitors, centrally acting antihypertensives, and alpha blockers.

KEY INSIGHTS PROVIDED: Factors influencing disease management and treatment decisions; drivers of and constraints on treatment selection; physician-reported treatment practices; rationale for changes in treatment approach; physician insight on persistency and compliance; physician-reported recent/anticipated changes in treatment approach.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…